Anna Berkenblit
2021
In 2021, Anna Berkenblit earned a total compensation of $2.5M as Senior Vice President and Chief Medical Officer at ImmunoGen, a 57% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $141,368 |
|---|---|
| Option Awards | $1,863,213 |
| Salary | $496,237 |
| Other | $9,672 |
| Total | $2,510,490 |
Berkenblit received $1.9M in option awards, accounting for 74% of the total pay in 2021.
Berkenblit also received $141.4K in non-equity incentive plan, $496.2K in salary and $9.7K in other compensation.
Rankings
In 2021, Anna Berkenblit's compensation ranked 5,137th out of 12,415 executives tracked by ExecPay. In other words, Berkenblit earned more than 58.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,137 out of 12,415 | 59th |
Division Manufacturing | 2,163 out of 5,505 | 61st |
Major group Chemicals And Allied Products | 932 out of 2,375 | 61st |
Industry group Drugs | 833 out of 2,096 | 60th |
Industry Pharmaceutical Preparations | 597 out of 1,546 | 61st |
Pay ratio
| Anna Berkenblit's Pay | $2,510,490 |
|---|---|
| Median Employee's Pay | $296,859 |
| Pay Ratio | 8to 1 |
In 2021, the annual total compensation of Anna Berkenblit was $2,510,490.
The annual total compensation of the median employee at ImmunoGen was $296,859.
The ratio of Anna Berkenblit's pay to the pay of median employee was therefore 8 to one.
Source: SEC filing on April 26, 2022.
Berkenblit's colleagues
We found four more compensation records of executives who worked with Anna Berkenblit at ImmunoGen in 2021.